

## Our Global Presence

With our extensive network of facilities in North America and Europe, **Patheon has the capacity, expertise and capabilities** to serve the growing outsourcing needs of the pharmaceutical industry.

### Three successful product launches

During 2006, three new products that Patheon had developed on behalf of clients were approved and launched into commercial production at Toronto Region, Whitby and Swindon.



## Canada

### Toronto Region Operations\*

**Key facts:**

- 728 employees
- 263,000 square feet
- High-potency, special compounds handling, solid, semi-solid and liquid dosage forms

### Toronto York Mills Operations

**Key facts:**

- 221 employees
- 160,000 square feet
- Solid, semi-solid and liquid dosage forms

### Whitby Operations

**Key facts:**

- 428 employees
- 199,000 square feet
- Solid, powder and liquid dosage forms

### Burlington – Century Operations

**Key facts:**

- 124 employees
- 45,000 square feet
- Solid dosage forms
- Central laboratory services

### Burlington – Gateway Operations

**Key facts:**

- 58 employees
- 22,800 square feet
- Powders

### Niagara Region Operations

**Key facts:**

- 259 employees
- 132,800 square feet
- Solid, semi-solid and liquid dosage forms

## United States

### Cincinnati Operations\*

**Key facts:**

- 579 employees
- 495,700 square feet
- Solid, semi-solid and liquid dosage forms, controlled/sustained release, liquid-filled hard capsules

### Caguas\* (Puerto Rico)

**Key facts:**

- 730 employees
- 250,000 square feet
- Solid, semi-solid and liquid dosage forms

### Manatí (Puerto Rico)

**Key facts:**

- 282 employees
- 410,000 square feet
- Solid dosage forms

### Carolina (Puerto Rico)

**Key facts:**

- 442 employees
- 230,000 square feet
- Oral cephalosporin solid dosage forms




### Patheon selected as strategic supplier

In January 2006, Patheon was selected by Merck & Co., Ltd to provide both drug development and commercial manufacturing services as part of a five-year strategic supply agreement.

\* Includes integrated PDS Centre of Excellence

### New facility completed

At Swindon, a new 65,000 square foot facility dedicated to manufacturing lyophilized cephalosporins was completed on time and on budget.



## Europe

### Swindon Operations\* (United Kingdom)

**Key facts:**

- 609 employees
- 366,300 square feet
- Sterile liquids, sterile powdered cephalosporins, semi-solid dosage forms
- Lyophilized cephalosporins

### Bourgoin-Jallieu Operations (France)

**Key facts:**

- 276 employees
- 272,000 square feet
- Solid and liquid dosage forms

### Ferentino Operations\* (Italy)

**Key facts:**

- 309 employees
- 144,000 square feet
- Sterile lyophilized and sterile liquid (parenteral) dosage forms

### Monza Operations (Italy)

**Key facts:**


- 495 employees
- 344,000 square feet
- Sterile lyophilized, sterile liquids, solid and liquid dosage forms



### Product transfers well underway


In Italy and France, work continued on an ambitious project to transfer more than 25 Rx products from two major clients into Patheon's facilities.

**Client Mix**  
(% of revenues)



■ Global Pharma ■ Specialty Pharma ■ Biotech

**Revenues by Geographic Region**  
(based on clients' billing addresses)  
(% of total revenues)



■ U.S. ■ Europe and Other ■ Canada